Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
Mölnlycke continuously evaluates its portfolio and operating model to ensure the business is well positioned to serve both healthcare professionals and patients in the best possible way. Having delivered sustained growth across its current business areas – Wound Care, ORS, Gloves and Antiseptics – the Board has concluded that changing market dynamics, customer needs and value drivers are best addressed by operating as two standalone companies, each with sharper strategic focus, clearer accountability and greater speed of execution:
- Mölnlycke – comprising the Wound Care and Antiseptics businesses, will focus on accelerating innovation and investments addressing strategic priorities and changing customer needs. The business benefits from market-leading solutions, an established global customer base and resilient end markets. In 2025, Wound Care and Antiseptics generated net sales of c. €1.3 billion and an EBITDA margin of c. 38%.
- Mölnlycke Surgical – comprising the ORS and Gloves businesses, will focus on improving efficiency, safety and outcomes in surgical settings. The business has well established positions in key segments, a strong manufacturing footprint and benefits from continued investments in product and service innovation. In 2025, ORS and Gloves generated net sales of c. €0.8 billion and an EBITDA margin of c. 11%.
“Our ongoing assessment of Mölnlycke’s portfolio has highlighted the opportunity for two strong standalone companies, each with the focus, accountability and resources to realise its full potential and be better positioned to create long-term value,” says Karl-Henrik Sundström, Chair of the Board of Directors at Mölnlycke.
Guillaume Joucla, Interim CEO, Mölnlycke adds “We are making this move from a position of strength. Greater focus will allow both companies to move faster, invest with greater clarity and respond more effectively to evolving customer needs.”
Following the creation of Mölnlycke Surgical, the intention is that Mölnlycke and Mölnlycke Surgical will become two standalone portfolio companies under Patricia Industries’ ownership. The separation is expected to be completed during 2027, subject to customary approvals.
Each company’s capitalisation will be assessed during the process with the ambition that both companies will have a capitalisation level suited for their respective business needs, and that Mölnlycke will maintain its investment grade rating.
Mölnlycke will provide further information, including expectations on potential organisational impact, as the process proceeds.
For more information, please contact:
Latest news
-
Major Scottish Hospital Adopts Steriwave®
UK’s Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
-
Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China
Gothenburg, Sweden, and Shanghai, China. 21 May 2026.
Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world’s fastest-growing wound care markets. The joint venture, majority-owned by Mölnlycke, will integrate the two companies’ wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China. -
Simple glove change could save the NHS £45 million over five years and improve caesarean safety
Gothenburg, Sweden. 27 April 2026. A new study1 published in the Journal of Hospital Infection shows that introducing a simple glove change during caesarean birth could deliver millions in cost savings for the National Health Service (NHS) in England.
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
-
Mölnlycke Health Care annual report 2025 highlights sustainable growth and strategic transformation
Gothenburg, Sweden. 1 April 2026. Today, Mölnlycke Health Care has published its annual report 2025, including sustainability report, outlining the company’s continued focus on revolutionising care for people and planet.
-
Europe faces a growing chronic wound crisis – time to act is now
Gothenburg, Sweden. 31 March 2026. Mölnlycke®, a global leader in MedTech, today welcomes the publication of Shaping the future of wound care in Europe, the first joint industry white paper from the MedTech Europe Wound Care Sector Working Group. The wound paper highlights the growing burden of chronic wounds and urges EU policymakers to elevate wound care as a strategic health priority across the EU.
-
Mölnlycke Health Care AB: CEO, Zlatko Rihter, announces resignation, Guillaume Joucla appointed interim CEO
Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO.